Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher
Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.
How this was made
The 30-second read
Why it matters
Earnings beats and guidance lifts for Lilly, Regeneron, and AstraZeneca are the primary drivers of the ETF's 3.28% monthly gain.
Market read
The article provides fresh earnings data for three large pharma stocks, directly affecting the THNR ETF and the broader weight‑loss sector.
What to watch
Regulatory scrutiny on obesity drugs and potential competition from emerging therapies could temper upside.
Background
The THNR ETF tracks a basket of weight‑loss drug companies; recent earnings beats have driven its outperformance.
Ticker impact
Eli Lilly posted Q3 revenue of $24.4B beating forecasts and raised its 2026 revenue outlook, driving a 22.5% stock rise.
likely upward pressure as investors price in higher revenue outlook
Earnings beat and guidance lift are fresh primary disclosures for a large‑cap stock.
Regeneron reported Q3 revenue of $5.1B, up 36%, and highlighted progress in obesity Phase‑3 trials, contributing a 22.4% stock gain.
upward bias as market digests strong top‑line and pipeline news
Primary earnings data and clinical‑trial update for a large‑cap biotech.
AstraZeneca beat Q3 sales and profit forecasts and announced $1.5B annual cost savings, sparking a 15.6% stock jump.
upward pressure as investors reward earnings beat and margin improvement
Fresh earnings and strategic guidance for a major pharma.
Novo Nordisk, the second‑largest THNR holding, gained 5.5% in October despite Lilly’s trial results against Ozempic.
limited directional bias absent new catalyst
No new company‑specific news, only relative performance.
Structure Therapeutics Inc. dropped 30.1% during the month, hurting the THNR index.
downward bias for the stock and related sector
Notable price move disclosed as primary data.
Viking Therapeutics lost 16.3% in October, contributing to the index’s underperformance.
likely continued pressure absent new catalyst
Price decline reported but no additional company news.
Market effects
Weight‑loss drug sector gains momentum from strong earnings and pipeline updates, boosting related ETFs.
U.S. and European pharma stocks see uplift, while Asian weight‑loss players lag.
Broad interest in obesity treatments may influence global health‑care allocations.
Counterpoint
Investors may be wary of valuation spikes after rapid price gains; a pull‑back could be imminent.
Key entities
- companyEli Lilly
Largest THNR holding, posted strong Q3 results.
- companyRegeneron Pharmaceuticals
Second‑largest THNR holding, strong earnings and trial progress.
- companyAstraZeneca
Major THNR component, beat forecasts and announced cost cuts.
